These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11204017)

  • 1. [Comparative study of the effect of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study].
    Eleuteri E
    Ital Heart J Suppl; 2000 Jun; 1(6):830-1. PubMed ID: 11204017
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).
    Anderson TJ; Elstein E; Haber H; Charbonneau F
    J Am Coll Cardiol; 2000 Jan; 35(1):60-6. PubMed ID: 10636260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background rationale for a study to assess normalization of brachial artery forearm flow function.
    Charbonneau F
    Can J Cardiol; 1998 Jul; 14 Suppl D():16D-17D. PubMed ID: 9713422
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors, calcium blockers, estrogen and antioxidants in secondary prevention of coronary disease.
    Vogel R
    Can J Cardiol; 1998 Jul; 14 Suppl D():8D-10D. PubMed ID: 9713419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current trials on angiotensin-converting enzyme inhibitors and endothelial dysfunction.
    Anderson T
    Can J Cardiol; 1998 Jul; 14 Suppl D():33D-34D. PubMed ID: 9713430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
    Rockx MA; Haddad H
    Curr Opin Cardiol; 2007 Mar; 22(2):128-32. PubMed ID: 17284992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelium: a new target for cardiovascular therapeutics.
    Deedwania PC
    J Am Coll Cardiol; 2000 Jan; 35(1):67-70. PubMed ID: 10636261
    [No Abstract]   [Full Text] [Related]  

  • 11. [Endothelial dysfunction and angiotensin-converting enzyme inhibitors in coronary disease].
    Mélon P
    Rev Med Liege; 1998 Jun; 53(6):353-4. PubMed ID: 9713215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinapril demonstrates improved endothelium-mediated vasodilation in patients with chronic heart failure.
    Compr Ther; 1998 Jan; 24(1):38. PubMed ID: 9452901
    [No Abstract]   [Full Text] [Related]  

  • 13. [Protective strategy of vascular endothelium].
    Tang CS; Lin L
    Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(2):89-90. PubMed ID: 12817574
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.
    Swales P; Williams B
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):79-89. PubMed ID: 12228847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
    Gojanovic B; Feihl F; Liaudet L; Waeber B
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression.
    Schmeisser A; Soehnlein O; Illmer T; Lorenz HM; Eskafi S; Roerick O; Gabler C; Strasser R; Daniel WG; Garlichs CD
    Biochem Biophys Res Commun; 2004 Dec; 325(2):532-40. PubMed ID: 15530425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertensive patients with signs of coronary heart disease. An ACE inhibitor improves endothelial function].
    MMW Fortschr Med; 2001 Aug; 143(33-34):58-9. PubMed ID: 11561465
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
    Yavuz D; Koç M; Toprak A; Akpinar I; Velioğlu A; Deyneli O; Haklar G; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):197-203. PubMed ID: 14608527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of ACE inhibition on coronary endothelial dysfunction.
    Nickenig G; Stäblein A; Wassmann S; Wyen C; Müller C; Böhm M
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):361-4. PubMed ID: 11967824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.